Immune Assessment Today: Optimizing and Standardizing Efforts to Monitor Immune Responses in Cancer and Beyond

As part of a symposium, current and former directors of Immune Monitoring cores and investigative oncologists presented insights into the past, present and future of immune assessment. Dr. Gnjatic presented a classification of immune monitoring technologies ranging from universally applicable to exp...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-01, Vol.16 (3), p.475
Main Authors: Pandey, Surya, Cholak, Meghan E, Yadali, Rishita, Sosman, Jeffrey A, Tetreault, Marie-Pier, Fang, Deyu, Pollack, Seth M, Gnjatic, Sacha, Obeng, Rebecca C, Lyerly, H Kim, Sonabend, Adam M, Guevara-Patiño, José A, Butterfield, Lisa H, Zhang, Bin, Maecker, Holden T, Le Poole, I Caroline
Format: Article
Language:English
Subjects:
Antigens
Biomarkers
Cancer
Cancer immunotherapy
Cancer therapies
CD8 antigen
Cell viability
Clinical outcomes
Clinical trials
Cytokines
Dendritic cells
Glioblastoma
Gliomas
Hypoxia
Immune response
Immunotherapy
Kinases
Lymphocytes
Lymphocytes T
Medical prognosis
Melanoma
Patients
T cells
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As part of a symposium, current and former directors of Immune Monitoring cores and investigative oncologists presented insights into the past, present and future of immune assessment. Dr. Gnjatic presented a classification of immune monitoring technologies ranging from universally applicable to experimental protocols, while emphasizing the need for assay harmonization. Dr. Obeng discussed physiologic differences among CD8 T cells that align with anti-tumor responses. Dr. Lyerly presented the Soldano Ferrone lecture, commemorating the passionate tumor immunologist who inspired many, and covered a timeline of monitoring technology development and its importance to immuno-oncology. Dr. Sonabend presented recent achievements in glioblastoma treatment, accentuating the range of monitoring techniques that allowed him to refine patient selection for clinical trials. Dr. Guevara-Patiño focused on hypoxia within the tumor environment and stressed that T cell viability is not to be confused with functionality. Dr. Butterfield accentuated monitoring of dendritic cell metabolic (dys)function as a determinant for tumor vaccine success. Lectures were interspersed with select abstract presentations. To summarize the concepts, Dr. Maecker from Stanford led an informative forum discussion, pointing towards the future of immune monitoring. Immune monitoring continues to be a guiding light towards effective immunotherapeutic strategies.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16030475